The national health spending watchdog is set to re-evaluate its decision on two pioneering Alzheimer's drugs following successful appeals from their manufacturers.
Donanemab and lecanemab, licensed for use in the UK in 2024, were initially deemed too expensive for NHS provision by the National Institute for Health and Care Excellence (Nice).